Late Breaking Abstract - CSL787, a novel nebulized IgG therapy, in patients with bronchiectasis: a Phase 1 trial - Amsterdam 2025

Advances in bronchiectasis: inflammation, infection and intervention

Chair(s): Stefano Aliberti, Michael Loebinger

Session type: Oral presentation

Late Breaking Abstract - CSL787, a novel nebulized IgG therapy, in patients with bronchiectasis: a Phase 1 trial

Damian G. Downey

EVENTS HOME

Previous presentation

Next presentation

Session content

Late Breaking Abstract - CSL787, a novel nebulized IgG therapy, in patients with bronchiectasis: a Phase 1 trial

Damian G. Downey

Replay

Poster

Abstract

Slides

Efficacy and safety of brensocatib in patients with non-cystic fibrosis bronchiectasis by exacerbation history: Analysis of the ASPEN trial

Michael Loebinger

Replay

Poster

Abstract

Slides

A bispecific monoclonal antibody targeting Pseudomonas aeruginosa in bronchiectasis: results from the GREAT-2 trial

Merete Bridget Long

Replay

Abstract

Slides

Airway epithelial integrity in bronchiectasis (BE): Preliminary data from the BRILLIANT study

Erin Cant

Replay

Abstract

Slides

Amplified aberrant small airway basal stem cells contribute to pathogenesis of bronchiectasis

Wei Rao

Replay

Abstract

Slides

Geographic variation and clinical correlates of the bronchiectasis mycobiome: Data from the EMBARC-BRIDGE study

Kai Xian Thng

Replay

Poster

Abstract

Slides

Characterising systemic inflammation in patients with bronchiectasis: data from the EMBARC BRIDGE study

Chloe Hughes

Replay

Abstract

Slides

The frequent exacerbator phenotype in bronchiectasis revisited: Data from the European Bronchiectasis Registry (EMBARC)

Oriol Sibila Vidal

Replay

Poster

Abstract

Slides

Identifying Predictors of Response to Pulmonary Rehabilitation in Bronchiectasis: A Prospective Study

Ilaria Prete

Replay

Poster

Abstract

Slides

Transcriptomics of air-liquid interface epithelial cultures derived from bronchiectasis patients in the EMBARC-BRIDGE study reveals novel dysregulated pathways

Max Schwiening

Replay

Poster

Abstract

Slides

Discussion and Q&A

Replay

CDN Connection Issue

The ERS Congress 2025, Amsterdam

#{title}